|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0022688,
umls-concept:C0033325,
umls-concept:C0039198,
umls-concept:C0061878,
umls-concept:C0185117,
umls-concept:C0332291,
umls-concept:C0376515,
umls-concept:C0456603,
umls-concept:C0681842,
umls-concept:C1333064,
umls-concept:C1416467,
umls-concept:C1416989,
umls-concept:C1422572,
umls-concept:C1424810,
umls-concept:C1511636,
umls-concept:C2911684
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2007-11-20
|
|
pubmed:abstractText |
We studied the prognostic importance of tumor-infiltrating regulatory T lymphocytes (Tregs) and cytotoxic T/NK lymphocytes (CTLs) in 98 diagnostic biopsy specimens from patients with classical Hodgkin lymphoma (cHL). Immunohistochemical analysis was performed for FOXP3 to identify Tregs and for granzyme B (GrB) to identify activated CTLs. Failure-free survival (FFS) and overall survival (OS) were clinical end points. Patients with fewer than 25 FOXP3+ cells per high-power field (HPF) had a mean +/- SD 5-year FFS of 64% +/- 7% vs 85% +/- 5% for patients with 25 or more FOXP3+ cells/HPF (P = .05). A FOXP3/GrB ratio of 1 or less was associated with poor FFS (46% +/- 10% vs 86% +/- 4%; P < .001) and OS (67% +/- 10% vs 93% +/- 3%; P < .001). When prior available MAL and bcl-2 expression data were included in a multivariate analysis of all clinical and biologic factors, a FOXP3/GrB ratio of 1 or less and tumor cell expression of MAL and bcl-2 all independently predicted poor FFS. This demonstrates the importance of evaluating tumor cell markers and the tumor immune infiltrate when considering biologic prognostic markers in cHL.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/FOXP3 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Forkhead Transcription Factors,
http://linkedlifedata.com/resource/pubmed/chemical/Granzymes,
http://linkedlifedata.com/resource/pubmed/chemical/MAL protein, T-cell,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Transport Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Myelin Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proteolipids,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-bcl-2,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0002-9173
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
128
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
958-65
|
|
pubmed:meshHeading |
pubmed-meshheading:18024321-Adolescent,
pubmed-meshheading:18024321-Adult,
pubmed-meshheading:18024321-Aged,
pubmed-meshheading:18024321-Aged, 80 and over,
pubmed-meshheading:18024321-Cell Count,
pubmed-meshheading:18024321-Child,
pubmed-meshheading:18024321-Child, Preschool,
pubmed-meshheading:18024321-Female,
pubmed-meshheading:18024321-Forkhead Transcription Factors,
pubmed-meshheading:18024321-Granzymes,
pubmed-meshheading:18024321-Hodgkin Disease,
pubmed-meshheading:18024321-Humans,
pubmed-meshheading:18024321-Killer Cells, Natural,
pubmed-meshheading:18024321-Lymphocytes, Tumor-Infiltrating,
pubmed-meshheading:18024321-Male,
pubmed-meshheading:18024321-Membrane Transport Proteins,
pubmed-meshheading:18024321-Middle Aged,
pubmed-meshheading:18024321-Myelin Proteins,
pubmed-meshheading:18024321-Neoplasm Staging,
pubmed-meshheading:18024321-Proteolipids,
pubmed-meshheading:18024321-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:18024321-Retrospective Studies,
pubmed-meshheading:18024321-Survival Rate,
pubmed-meshheading:18024321-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:18024321-T-Lymphocytes, Regulatory,
pubmed-meshheading:18024321-Tissue Array Analysis,
pubmed-meshheading:18024321-Tumor Markers, Biological
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression.
|
|
pubmed:affiliation |
Department of Clinical Pathology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA.
|
|
pubmed:publicationType |
Journal Article
|
